Sarcoma News

The FDA granted orphan drug designation to Triolimus for the treatment of patients with angiosarcoma, according to a press release from the drug’s manufacturer.

Patients with soft tissue sarcoma who received trabectedin until disease progression demonstrated significantly improved PFS and OS compared with patients who only received six cycles of treatment, according to study results.

The use of preoperative image-guided radiation therapy was associated with a reduction in late toxicities among patients with extremity soft tissue sarcoma, according to study results.

Recent data suggest longer duration of treatment with protease inhibitors boosted with Norvir was associated with a reduced incidence of Kaposi sarcoma among veterans with HIV after at least 1 year of treatment.

More than 230 drugs appeared on the American Society of Health-System Pharmacists’ drug shortage list as of mid-January.

The FDA has granted priority review to Yondelis for the treatment of patients with advanced soft tissue liposarcoma and leiomyosarcoma who have received prior chemotherapy including an anthracycline, according to a press release issued by the drug’s manufacturer.

Patients with chordomas or chondrosarcomas of the skull base had favorable 5-year OS and local control after high-dose image-guided intensity-modulated radiation therapy, according to study results.

The use of preoperative transcutaneous oximetry may be useful in predicting wound-healing complications in patients undergoing surgery for soft tissue sarcomas after external beam radiation therapy, according to study findings.

The FDA granted fast track designation to TH-302 as a potential treatment for previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma, the drug’s manufacturer announced.

Shorter-duration therapy with vincristine, dactinomycin and lower-dose cyclophosphamide with radiation therapy did not compromise failure-free survival in patients with low-risk embryonal rhabdomyosarcoma, according to results of a noninferiority trial.